

PATENTS

#8/a
DmT
7-25-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of
François HIRSCH et al.
Serial No. (unknown)
Filed herewith

Box PCT
Application Branch

NF-κB ACTIVATION
INHIBITORS, AND THEIR
PHARMACEUTICAL USES

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to the first Official Action and calculation
of the filing fee, please amend the above-identified applica-
tion as follows:

IN THE CLAIMS:

Amend claim 3 as follows:

--3. (amended) The use according to claim 1, of compounds
inhibiting the activation of MF-κB connected specifically to the
transmembranal receptors of the cytokins of class I in the cells of the
organism, such as compounds selected from growth hormone or
erythropoietin.--

{ Amend claim 4 as follows: }

--4. (amended) The use according to claim 1:
- of the human growth hormone, as obtained by extraction from
hypophysary extracts, and purification,